MARKET

ACHV

ACHV

Achieve
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.15
+0.02
+0.21%
Closed 16:09 01/26 EST
OPEN
7.27
PREV CLOSE
7.14
HIGH
7.63
LOW
7.08
VOLUME
33.91K
TURNOVER
--
52 WEEK HIGH
16.10
52 WEEK LOW
6.55
MARKET CAP
67.59M
P/E (TTM)
-1.5391
1D
5D
1M
3M
1Y
5Y
Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation
Achieve Life Sciences Inc (NASDAQ: ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation. The trial will evaluate the efficacy and safety of 3 mg cytisinicline dosed three times daily compared to placebo in 75...
Benzinga · 1d ago
Achieve Life commences Phase 3 trial of cytisinicline for smoking cessation
Achieve Life Sciences (NASDAQ:ACHV) has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in U.S. ORCA-3 will evaluate the efficacy and safety of
Seekingalpha · 1d ago
Achieve Life Sciences Announces Initiation Of The Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline For Smoking Cessation
Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced
Benzinga · 1d ago
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation ...
GlobeNewswire · 1d ago
Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference
SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, to...
GlobeNewswire · 01/06 13:30
Achieve Life Sciences Announces Completion Of Last Subject, Last Follow-Up Visit In Phase 3 ORCA-2 Trial Of Cytisinicline For Smoking Cessation
Achieve Life Sciences, Inc.
Benzinga · 01/04 13:33
BRIEF-SVB Financial Group Reports 14.5% Passive Stake In Achieve Life Sciences
reuters.com · 12/29/2021 21:25
Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program
Achieve Life Sciences Inc (NASDAQ: ACHV) has 
Benzinga · 12/22/2021 17:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACHV. Analyze the recent business situations of Achieve through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
71.43%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACHV stock price target is 31.50 with a high estimate of 58.00 and a low estimate of 20.00.
High58.00
Average31.50
Low20.00
Current 7.15
EPS
Actual
Estimate
-1.22-0.92-0.61-0.31
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 47
Institutional Holdings: 2.44M
% Owned: 25.82%
Shares Outstanding: 9.45M
TypeInstitutionsShares
Increased
11
63.21K
New
8
122.97K
Decreased
9
171.42K
Sold Out
4
146.29K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.73%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
Chairman/Executive Director
Richard Stewart
President/Director
Cindy Jacobs
Chief Executive Officer/Director
John Bencich
Chief Accounting Officer
Jerry Wan
Chief Scientific Officer
Anthony Clarke
Lead Director/Independent Director
Donald Joseph
Independent Director
Bridget Martell
Independent Director
Martin Mattingly
Independent Director
Jay Moyes
No Data
About ACHV
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. It is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties.

Webull offers kinds of Achieve Life Sciences Inc stock information, including NASDAQ:ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.